Drug Trial Radar · NCT03646357
BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function
Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,895
Actual
Start
Oct 1, 2018
Primary completion
Apr 4, 2025
Study completion Dec 10, 2035
Sponsor
- Lead sponsor
- Oslo University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Vestre Viken Hospital Trust; The Hospital of Vestfold; University of Oslo; Helse Stavanger HF; Haukeland University Hospital; St. Olavs Hospital; University Hospital of North Norway; Sorlandet Hospital HF; Norwegian University of Science and Technology; Sykehuset Innlandet HF; Nordlandssykehuset HF; Lovisenberg Diakonale Hospital; Diakonhjemmet Hospital; Ostfold Hospital Trust
- First posted
- Aug 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to investigate whether oral betablocker (BB) therapy is superior to no such treatment following an acute myocardial infarction (AMI).
Conditions
- Acute Myocardial Infarction
- Non-ST Elevation Myocardial Infarction
- ST Elevation Myocardial Infarction
Interventions
Non-betablockerOther
No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.
BetablockerDrug
A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be: * Metoprolol succinate up to a total dose of 200mg daily * Bisoprolol up to a total dose of 10mg daily * Carvedilol up to a total dose of 50mg daily The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- A composite of death of any cause, recurrent myocardial infarction, incident heart failure, coronary revascularization, ischemic stroke, malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac originTime frame: 6 months (minimum) to 6 years (maximum)
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Sørlandet Sykehus
Arendal, Norway
Haukeland Universitetssykehus
Bergen, Norway
Nordlandssykehuset HF Bodø
Bodø, Norway
Drammen Hospital
Drammen, Norway
Sykehuset Østfold Kalnes
Fredrikstad, Norway
Sykehuset Innlandet HF, Gjøvik Sykehus
Gjøvik, Norway
Sykehuset Innlandet Hamar
Hamar, Norway
Vestre Viken HF, Ringerike Sykehus
Hønefoss, Norway
Sykehuset Innlandet Lillehammer
Lillehammer, Norway
AHUS
Lørenskog, Norway
LHL Gardermoen
Lørenskog, Norway
Diakonhjemmet Sykehus
Oslo, Norway
Lovisenberg Diakonale Sykehus
Oslo, Norway
Oslo University Hospital Rikshospitalet, Dept.of Cardiology
Oslo, Norway
Oslo University Hospital Ullevaal, Dept. of Cardiology
Oslo, Norway
Vestre Viken HF, Bærum Sykehus
Sandvika, Norway
Stavanger Universitetssjukehus
Stavanger, Norway
Vestfold hospital
Tønsberg, Norway
Universitetssykehuset Nord-Norge, UNN
Tromsø, Norway
St. Olavs University Hospital
Trondheim, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.